Evaxion Biotech
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 49
- Market Cap
- -
- Introduction
Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen M?ller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.
Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
- Conditions
- Melanoma Stage IIIMelanoma Stage IV
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Evaxion Biotech A/S
- Target Recruit Count
- 90
- Registration Number
- NCT05309421
- Locations
- 🇦🇺
Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
🇦🇺Ballarat Health Services (Grampians Health), Ballarat Central, Victoria, Australia
🇦🇺One Clinical Research, Nedlands, Western Australia, Australia
Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1
- Conditions
- Melanoma Stage IVMelanoma Stage III
- Interventions
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Evaxion Biotech A/S
- Target Recruit Count
- 15
- Registration Number
- NCT04455503
- Locations
- 🇦🇺
Liverpool Hospital, Goulburn, New South Wales, Australia
🇦🇺Flinders Medical Centre, Adelaide, South Australia, Australia
🇦🇺Monash Medical Centre, Clayton, Victoria, Australia
News
ExpreS2ion Biotech Advances to Clinical Phase with HER2 Breast Cancer Vaccine, Reports Strong Q4 2024 Progress
• ExpreS2ion Biotech secured crucial approval for Phase I clinical trial of ES2B-C001, their novel HER2-expressing breast cancer therapeutic vaccine, marking their entry into clinical development. • The company's collaboration with University of Oxford yielded positive Phase 2b malaria vaccine results, published in The Lancet Infectious Diseases, showing promise in meeting WHO's 75% efficacy goal. • ExpreS2ion strengthened its financial position through successful TO 10 warrants exercise, raising approximately SEK 10 million, while maintaining a cash balance of SEK 81.5 million by end of 2024.
Evaxion's AI-Immunology Platform Validated Across Multiple Clinical Trials
Evaxion Biotech's AI-Immunology™ platform demonstrates strong ability to select clinically relevant vaccine targets across three clinical trials.